Tokyo Tape
Sign in
← Sumitomo Chemical

Half-year report · Q2

4005.TEDINET S100UN1U
Period2024-04-01 → 2024-09-30
Filed2024-11-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥1.24T2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥2.45T2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.19T2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥121.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income−¥133.7bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax−¥30.5bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥462.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥103.8bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)−¥6.5bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥311.8bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥76.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥20.3bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income−¥465.4bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS (5-year summary)
Net income−¥107.0bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥3.72Tat 2024-09-30Cons.Assets IFRS
Total assets¥3.93Tat 2024-03-31Cons.Assets IFRS
Total assets¥4.38Tat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.63Tat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥2.77Tat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥1.09Tat 2024-09-30Cons.Equity IFRS
Net assets / equity¥1.16Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.55Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31dCons.Equity IFRS
Equity (owners)¥909.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥965.8bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.22Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥273.4bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥217.4bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥277.7bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥63.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥51.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥115.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥74.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥112.2bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥79.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥75.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥49.2bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥140.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-3.992024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-190.692023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-46.692023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
Equity ratio24.5%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.5%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio27.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥78.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥41.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥37.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30¥15.7bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥50.2bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥50.2bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥10.0bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2024-04-01 → 2024-09-30¥147.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2024-04-01 → 2024-09-30¥138.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥8.7bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2024-04-01 → 2024-09-30¥8.7bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2024-04-01 → 2024-09-30¥405.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2024-04-01 → 2024-09-30¥403.0bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥36.6bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥239.5bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥238.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥13.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2024-04-01 → 2024-09-30¥224.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2024-04-01 → 2024-09-30¥224.3bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥235m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2024-04-01 → 2024-09-30¥37.5bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥195.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥195.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30¥470m
—segment totalrevenue2024-04-01 → 2024-09-30¥1.21T
—segment totalrevenue external2024-04-01 → 2024-09-30¥1.20T
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥13.0bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥23.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥76.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥34.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥41.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥4.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥7.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-09-30¥159.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-09-30¥149.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥9.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.5bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-09-30¥393.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-09-30¥390.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥44.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥243.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥241.2bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-09-30¥203.9bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-09-30¥203.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥220m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-09-30¥17.8bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥65.5bn
—segment totalrevenue2023-04-01 → 2023-09-30¥1.17T
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.15T
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥14.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30−¥93.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 919
ItemContextValueUnit
Liabilities and equity IFRSPrior1YearInstant3934818000000JPY
Liabilities and equity IFRSCurrentQuarterInstant3719035000000JPY
Revenue IFRSPrior1YTDDuration1186875000000JPY
Revenue IFRSCurrentYTDDuration1241395000000JPY
Cost of sales IFRSPrior1YTDDuration930586000000JPY
Cost of sales IFRSCurrentYTDDuration891218000000JPY
Gross profit IFRSPrior1YTDDuration256289000000JPY
Gross profit IFRSCurrentYTDDuration350177000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration349216000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration300290000000JPY
Other operating income IFRSPrior1YTDDuration12411000000JPY
Other operating income IFRSCurrentYTDDuration36071000000JPY
Other operating expenses IFRSPrior1YTDDuration26255000000JPY
Other operating expenses IFRSCurrentYTDDuration17643000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-26908000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration52934000000JPY
Operating profit loss IFRSPrior1YTDDuration-133679000000JPY
Operating profit loss IFRSCurrentYTDDuration121249000000JPY
Finance income IFRSPrior1YTDDuration56548000000JPY
Finance income IFRSCurrentYTDDuration12283000000JPY
Finance costs IFRSPrior1YTDDuration26665000000JPY
Finance costs IFRSCurrentYTDDuration164071000000JPY
Profit loss before tax IFRSPrior1YTDDuration-103796000000JPY
Profit loss before tax IFRSCurrentYTDDuration-30539000000JPY
Income tax expense IFRSPrior1YTDDuration3252000000JPY
Income tax expense IFRSCurrentYTDDuration-10254000000JPY
Profit loss IFRSPrior1YTDDuration-107048000000JPY
Profit loss IFRSCurrentYTDDuration-20285000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration-76346000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-6527000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-30702000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-13758000000JPY
Profit loss IFRSPrior1YTDDuration-107048000000JPY
Profit loss IFRSCurrentYTDDuration-20285000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration-46.69
Basic earnings loss per share IFRSCurrentYTDDuration-3.99
Diluted earnings loss per share IFRSPrior1YTDDuration－
Diluted earnings loss per share IFRSCurrentYTDDuration－
Profit loss IFRSPrior1YTDDuration-107048000000JPY
Profit loss IFRSCurrentYTDDuration-20285000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration59084000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-21477000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-84000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-105000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration1043000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration1764000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration60043000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-19818000000JPY
Remeasurements of financial assets measured at fair value through other comprehensive income net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration－JPY
Remeasurements of financial assets measured at fair value through other comprehensive income net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-74000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass